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Abstract: Methylmalonic aciduria (MMA) is an inherited metabolic disease caused by methylmalonyl-
CoA mutase deficiency. Early-onset disease usually presents with a neonatal acute metabolic acidosis,
rapidly causing lethargy, coma and death if untreated. Late-onset patients have a better prognosis but
develop common long-term complications, including neurological deterioration, chronic kidney disease,
pancreatitis, optic neuropathy and chronic liver disease. Of note, oncogenesis has been reported anec-
dotally in organic acidurias. Here, we present three novel and two previously published cases of MMA
patients who developed malignant liver neoplasms. All five patients were affected by a severe, early-onset
form of isolated MMA (4 mut , 1 cblB subtype). Different types of liver neoplasms, i.e. hepatoblastoma
and hepatocellular carcinoma, were diagnosed at ages ranging from infancy to adulthood. We discuss
pathophysiological hypotheses involved in MMA-related oncogenesis such as mitochondrial dysfunction,
impairment of tricarboxylic acid cycle, oxidative stress, and effects of oncometabolites. Based on the
intriguing occurrence of liver abnormalities, including neoplasms, we recommend close biochemical and
imaging monitoring of liver disease in routine follow-up of MMA patients. This article is protected by
copyright. All rights reserved.
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Methylmalonic aciduria (MMA) is an inherited metabolic disease caused by methylmalonyl-
CoA mutase deficiency. Early-onset disease usually presents with a neonatal acute metabolic 
acidosis, rapidly causing lethargy, coma and death if untreated. Late-onset patients have a 
better prognosis but develop common long-term complications, including neurological 
deterioration, chronic kidney disease, pancreatitis, optic neuropathy and chronic liver disease. 
Of note, oncogenesis has been reported anecdotally in organic acidurias. Here, we present 
three novel and two previously published cases of MMA patients who developed malignant 
liver neoplasms. All five patients were affected by a severe, early-onset form of isolated 
MMA (4 mut
0
, 1 cblB subtype). Different types of liver neoplasms, i.e. hepatoblastoma and 
hepatocellular carcinoma, were diagnosed at ages ranging from infancy to adulthood. We 
discuss pathophysiological hypotheses involved in MMA-related oncogenesis such as 
mitochondrial dysfunction, impairment of tricarboxylic acid cycle, oxidative stress, and 
effects of oncometabolites. Based on the intriguing occurrence of liver abnormalities, 




including neoplasms, we recommend close biochemical and imaging monitoring of liver 
disease in routine follow-up of MMA patients. 
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Take home message 
Liver neoplasms are a complication in MMA and warrant regular monitoring. 
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Isolated methylmalonic aciduria (MMA) is an autosomal recessive disorder of propionate 
metabolism caused by mutations in the MMUT gene (mut subtype, OMIM: 251000) (Forny et 
al 2016) encoding methylmalonyl-CoA mutase (MUT, EC 5.4.99.2), which requires 
adenosylcobalamin as a cofactor. Failure to produce and deliver the cofactor to its target 
enzyme MMUT also results in MMA, involving mutations in the MMAA (cblA subtype, 
OMIM: 251100) and MMAB (cblB subtype, OMIM: 251110) genes. 
Patients either present an early-onset disease with acute neonatal decompensation, associated 
with lethargy, vomiting, hypotonia, metabolic acidosis and hyperammonaemia, or a late-onset 
with symptoms such as failure to thrive, anorexia, vomiting and developmental delay. 
Patients, even when treated early, are at risk of long-term complications (Horster et al 2007), 
i.e. acute or chronic basal ganglia injury, white matter disease, optic neuropathy, tubulo-
interstitial nephritis leading to progressive renal failure, cardiomyopathy and pancreatitis. 
Recent guidelines have defined management of MMA patients, including monitoring and 
treatment of those complications (Baumgartner et al 2014). 
MMUT has an anaplerotic role in supplying succinyl-CoA to the tricarboxylic acid cycle and 
its expression is particularly high in the liver. Liver-transplanted MMA patients present a 
reduction of metabolic decompensations and lower plasma levels of intermediary metabolites 
inherent to the disease. Despite the significant role of the liver in MMA metabolism, hepatic 
complications have been scarcely described. A recent study reported on longitudinal 
elevations of alpha-fetoprotein, the occurrence of hyperechoic liver tissue on ultrasound, and 




marked pathological changes on liver biopsy, ranging from fibrosis to cirrhosis (Imbard et al 
2018). 
Here we present three unreported and two previously published cases of MMA patients 
(Cosson et al 2008; Chan et al 2015) who developed liver neoplasms (hepatoblastoma and/or 
hepatocellular carcinoma). We discuss possible pathogenic mechanisms leading to 
oncogenesis in MMA and provide recommendations on monitoring liver complications in 
MMA patients. 
 
Patients and results 
We present the detailed medical history for patients 1-3 and a summary of new and previously 
published cases (Table 1). 
Case 1 
Patient 1 was born at term from non-consanguineous Caucasian parents. She presented at the 
age of 10 days with collapse and metabolic acidosis, requiring resuscitation, but diagnostic 
investigations were not conclusive. Subsequently she was noted to have motor developmental 
delay and presented again with vomiting and poor feeding at the age of 9 months, when the 
diagnosis of MMA was confirmed, showing compound heterozygous mutations in the MMAB 
gene (c.556C>T, c.643A>G). Conventional treatment was initiated, resulting in metabolic 
control, but she developed stage 4 chronic kidney disease. At 16 years of age, she required 
haemodialysis. Subsequently, she became more unstable and had about 3-4 admissions per 
year for acute metabolic decompensations, one of which was complicated by a basal ganglia 




stroke, resulting in dysarthria and severe locomotor disability while her cognitive function 
was mainly spared. Ongoing nausea and occasional vomiting required a jejunostomy insertion 
to support nutrition. Her osteopenia (Z score of -5.7 at the spine, -5 at the total hip site, aged 
19 years) was treated with bisphosphonates. At 22 years of age, a severe metabolic 
decompensation led to significantly raised lactate and mild hyperammonaemia. Despite 
intensive clinical management, she deteriorated and passed away a few days later. 
Concomitantly a liver ultrasound had shown a small lesion in the liver. A post-mortem report 
confirmed hepatocellular carcinoma on a background of cirrhosis and steatosis, which could 
have contributed to her poor acute treatment response. 
Case 2 
Patient 2 is the younger brother of an affected sibling sharing the diagnosis of mut
0
 MMA 
born to consanguineous parents. The index patient was diagnosed after neonatal presentation, 
had minor metabolic decompensations, but developed learning difficulties and autistic 
spectrum disorder. Parents opted out of prenatal genetic testing for patient 2, hence he was 
managed prospectively from birth. On antenatal scan he had been diagnosed with a right 
multicystic and dysplastic kidney, confirmed on postnatal ultrasound (Supp. Fig. 1AB) and 
magnetic resonance imaging (Supp. Fig. 1C), in addition depicting bilateral 
hydroureteronephrosis (Supp. Fig. 1CD). Postnatally, the diagnosis of MMA was confirmed 
(homozygous MMUT c.692dup) and the patient was started on conventional treatment. 
Despite metabolic stability, chronic mild hyperammonaemia around 150 µmol/L (Supp. Fig. 
2A) required long-term ammonia scavengers. During routine monitoring at four months of 
age, elevated liver enzymes (gamma-glutamyl transferase and alkaline phosphatase) (Supp. 




Fig. 2B) triggered detailed liver investigations, which revealed a heterogeneous, hyperechoic 
lesion (Fig. 1AB), as a mass in segment VII (Fig. 1C). Alpha-fetoprotein levels were peaking 
at a maximum of 23,780 ng/mL (reference <10) (Supp. Fig. 2C) and hepatoblastoma was 
detected in a liver biopsy. After multidisciplinary assessment, liver transplant was performed 
at six months of age, serving the dual purpose of removal of the tumour as well as supportive 
treatment of the underlying MMA. He received two subsequent courses of cisplatin to 
minimise the risk of metastases. Unexpectedly, the explanted liver showed foci of 
hepatocellular carcinoma in addition to hepatoblastoma. Screening for hepatitis B and C virus 
serotypes was negative. Intermittent post-transplant elevations of alanine and aspartate 
transaminases (Supp. Fig. 2D) were presumably caused by a viral infection, as transplant 
rejection and reoccurrence of tumour were excluded. Ten months post-transplant he remains 
relapse-free with no metabolic decompensations or complications from liver transplantation. 
Case 3 
Patient 3 presented a few days after birth with generalized hypotonia, hypothermia, and 
dyspnoea. Increased methylmalonic acid in urine led to the diagnosis of MMA, confirmed by 
1% of residual MMUT activity in cultured fibroblasts and compound heterozygous mutations 
in the MMUT gene (c.410C>T, c.655A>T). On a low-protein diet her metabolic control was 
satisfactory with 1-2 hospital admissions per year due to mild decompensations. She showed 
mild developmental delay, growth retardation and delayed puberty. She had low bone density 
(Z score of -2.0 at the spine, -2.1 at the total hip site, aged 30 years) and was diagnosed with 
Scheuermann’s disease as teenager. Around the same age she developed chronic kidney 
disease stage 4. At the age of 23 years she developed bilateral visual loss due to optic atrophy, 




and bilateral partial neurosensory hearing loss. Concurrently, she presented two episodes of 
deep venous thrombosis. At the age of 31 years, baseline investigations during a mild 
metabolic decompensation showed a suspicious lesion on liver ultrasound, which was 
unapparent during routine ultrasound monitoring ten years prior. Magnetic resonance imaging 
confirmed one lesion in segment VI and a smaller lesion in segment V/VI, which on liver 
biopsy was diagnostic of hepatocellular carcinoma (negative screening for hepatitis B and C 
virus serotypes). Positron emission tomography computed tomography imaging did not reveal 
any metastases and liver segments V and VI were resected without perioperative 
complications. Histological investigations of the tumour confirmed a completely necrotic 
hepatocellular carcinoma with signs of fibrosis in the surrounding liver tissue. 17 months after 
tumour resection she remained relapse-free but passed away at the age of 32 years due to the 
sequelae of an acute haemorrhagic pancreatitis. 
MMA severity and outcome 
All five patients included in the study (Table 1) presented during the first year of life without 
clinical hydroxocobalamin responsiveness. Common clinical findings included significant 
chronic kidney disease, high levels of plasma and urinary methylmalonic acid and markedly 
reduced MMUT activity in the cases investigated. Patients had comparable metabolic 
treatment with the mainstay of low protein diet, carnitine supplementation, and a glucose 
polymer-based emergency regime. The phenotypic severity in the presented cases is further 
underlined by the poor survival with three out of five patients having passed away between 
eleven (case 4) and 32 years (case 3) of age. In patients 1 and 4 the cause of death was partly 
attributed to the liver neoplasm. 





All mutations of cases 1-4 were previously associated with a severe phenotype, except for the 
novel MMAB mutation c.643A>G p.(Arg215Gly) in case 1. Case 2 was homozygous for a 
truncating mutation resulting in p.(Tyr231*), yielding no functional enzyme (Forny et al 
2016). The common severe catalytic mutant p.(Asn219Tyr) (Forny et al 2014) was found in 
cases 3 and 4. Case 3 also harboured the p.(Ala137Val) mutant, a mut
0
 allele in exon 3, which 
corresponds in a large part to the essential substrate-binding site of MMUT (Froese et al 
2010), whereas case 4 carried the severe catalytic and folding mutant p.(Ala191Glu) (Forny et 
al 2014) in a compound heterozygous state. Case 1, the only non-MMUT case, carried the 
common p.(Arg186Trp) MMAB mutant (Lerner-Ellis et al 2006) alongside the novel 
p.(Arg215Gly) mutant, affecting residue 215, which is directly involved in the formation of 
the active site. All mutations found are non-responsive to hydroxocobalamin treatment in vivo 
or supplementation in vitro, further emphasising the severity of the cases presented in this 
study. For case 5, no mutational information was available. 
Histological findings 
Microscopic studies revealed features of hepatoblastoma (cases 2, 4, 5) and hepatocellular 
carcinoma (cases 1-4); cases 2 and 3 were studied in more detail. The explanted liver of case 
2 displayed mixed hepatoblastoma (Fig. 2A) with mesenchymal aspects (Fig. 2B). 
Remarkably, hepatocellular carcinoma elements were also present, featuring focal 
cytoplasmic beta catenin expression, expression of glutamine synthetase, glypican3 (not 
shown) and canalicular expression of bile salt export pump (Fig. 2C) without evidence for 
congenital hepatic fibrosis. The liver biopsy of case 3 showed vast areas of necrosis and other 




hepatocellular carcinoma-typical elements, such as hepatocytic differentiation, loss of 
reticulin, and glutamine synthetase staining (Fig. 3A), indicative of carcinogenic WNT 
signalling, in line with detection of nuclear beta catenin (Fig. 3B). Upon liver resection, 
inflammation and necrosis were detected (Fig. 3C). Investigation of the lesion-surrounding 
tissue revealed portal and septal fibrosis and hepatocytes with glycogenated nuclei in cases 2 
and 3 (Fig. 2D, Fig. 3D). 
 
Discussion 
Clinical presentation and histological findings 
We describe three unreported cases of liver neoplasm associated with severe MMA 
presentation and reviewed two previously published patients. The five patient cohort carried 
mutations previously associated with severe phenotypes, presented an early-onset disease and 
renal, pancreatic and neurological complications. Liver neoplasms presented at ages ranging 
from 10 weeks (case 2, hepatoblastoma with areas of hepatocellular carcinoma) to 31 years 
(case 3, hepatocellular carcinoma) – both exceptionally early occurrences for these tumour 
entities. The concomitant finding of two different tumour entities (case 2) is intriguing as the 
mechanism of their emergence is fundamentally different. Hepatoblastoma and hepatocellular 
carcinoma develop by malignant transformation of foetal and well-differentiated hepatocytes, 
respectively. Cases 1-3 showed evidence of cirrhosis/fibrosis, as previously reported in MMA 
(Imbard et al 2018) and might per se increase the risk of developing liver neoplasms. 
Cirrhosis is a recognised complication in other inborn errors of metabolisms, such as Wilson 
disease, tyrosinaemia type I, argininosuccinic aciduria or glycogen storage disorders; the latter 




three diseases identified with significant risk of developing hepatocellular carcinoma (Schady 
et al 2015; Baruteau et al 2017; van Ginkel et al 2017). 
Toxic metabolites and mitochondrial dysfunction 
Mitochondrial dysfunction is a well-recognised pathophysiological mechanism in MMA: 
Megamitochondria, decreased mitochondrial mass, and impaired mitochondrial membrane 
potential in an animal model (Chandler et al 2009) and abnormal mitochondrial ultrastructure 
in patients (Wilnai et al 2014) have been reported. Increased fibroblast growth factor 21, a 
biomarker for mitochondrial disease, correlates with long-term complications in MMA 
(Manoli et al 2018). The mitochondrial pathophysiology is multifactorial (Fig. 4) (Kolker et al 
2013): i) Accumulating propionyl-CoA inhibits pyruvate dehydrogenase complex (Gregersen 
1981), succinate-CoA ligase, a key enzyme in producing and maintaining mitochondrial 
DNA, and the respiratory chain by a direct mechanism (Schwab et al 2006); ii) anaplerosis of 
the tricarboxylic acid cycle is impaired due to reduced succinyl-CoA production from 
defective MUT, causing a reduced tricarboxylic acid cycle flux to produce energy in 
mitochondria; iii) excessive 2-methylcitrate, produced from accumulating propionyl-CoA 
reacting with oxaloacetate, is a potent toxic metabolite, inhibiting various enzymes of the 
tricarboxylic acid cycle (Cheema-Dhadli et al 1975). 
Subsequently to mitochondrial impairment, increased production of reactive oxygen species is 
suspected to play a major role in numerous MMA complications, such as optic neuropathy 
(Pinar-Sueiro et al 2010), chronic renal failure (Manoli et al 2013), and chronic liver disease 
(de Keyzer et al 2009). Similarly, increased oxidative stress is likely to be involved in liver 
oncogenesis, causing DNA damage and activation of reactive oxygen species-dependent pro-




oncogenic signalling pathways, including autophagy (Azad et al 2009), nuclear factor κ-B 
signalling (Morgan and Liu 2011), hypoxia-inducible factor 1-alpha, mitogen-activated 
protein kinase/ERK cascade, and the phosphoinositide-3-kinase/AKT pathway (Kumari et al 
2018). 
Impact of oncometabolites 
While toxic metabolites cause chronic tissue damage, independently posing a cancer risk, 
oncometabolites inflict neoplastic vulnerability via their effect on key-enzymes regulating 
metabolic pathways facilitating cell survival or dedifferentiation, mimicking the effect of 
mutations in tumour suppressor genes or oncogenes (Erez and DeBerardinis 2015). MMA 
oncometabolites may alter genome expression, e.g. propionyl-CoA is known to modify 
histone acetylation (Nguyen et al 2007). So far, three oncometabolites have been identified in 
organic acidurias: fumarate (fumarate hydratase deficiency), succinate (succinate 
dehydrogenase deficiency) and D-2-hydroxyglutarate (D-2-hydroxyglutaric aciduria type I 
and II). While evidence of oncometabolites in MMA is lacking, renal cell carcinoma kidneys 
of an MMA patient were found to carry a somatic knock-out mutation for the TSC1 gene 
encoding hamartin (Potter et al 2017), shown to cause accumulation of fumarate (Drusian et al 
2018). Hence, further genomic investigations of case 2 might help to understand their 
presentation of a multicystic dysplastic kidney. In addition, environmental factors such as 
exposure to exogenous hepatotoxic compounds or oncogenic viruses are parameters that need 
to be carefully taken into consideration in discussing the causative pathophysiological 
mechanisms of liver oncogenicity. 




With regards to the liver, oncogenic processes might already be relevant before birth: 
Although the foetus benefits from maternal detoxification of toxic MMA metabolites in utero, 
preventing any systemic decompensation, the development of hepatoblastoma might be 
facilitated by the increased production of MMA-derived oncometabolites in situ, promoting 
oncogenicity in highly-proliferating foetal hepatocytes. Conversely, the development of 
hepatocellular carcinoma requires the transformation of mature hepatocytes, e.g. case 3. 
MMA might be another suitable disease model for the study of oncometabolites in inborn 
errors of metabolism. 
Recommendations for monitoring of liver disease in MMA 
Approximately 50% of MMA patients show liver abnormalities (Imbard et al 2018). Liver 
monitoring, which involves a combination of yearly (biannually during the first year of life) 
liver enzymes (ALT, AST, ALP, GGT), alpha fetoprotein, and detailed liver ultrasound is 
crucial in MMA to detect chronic liver disease and neoplasm, especially in early-onset 
patients, who are unresponsive to hydroxocobalamin treatment. Immunosuppression, e.g. as 
required after kidney transplant (see case 4), is an additional risk factor for malignant 
transformation, warranting distinct attention (Cosson et al 2008). A transplanted liver does not 
foster the genetic defect but is still exposed to a – although lower – level of toxic metabolites, 
hence monitoring for liver neoplasms is equally necessary in these cases. 
 





With improved survival of MMA patients in the last decades, there is an increasing need to 
monitor these patients for long-term complications. Development of liver neoplasms in MMA 
might be an under-appreciated phenomenon. Although longitudinal and functional studies are 
required to better understand the pathophysiology, the occurrence of liver neoplasms in MMA 
might be multifactorial, cumulating multiple oncogenic events favoured by mitochondrial 
dysfunction, impairment of tricarboxylic acid cycle, oxidative stress, effects of toxic 
metabolites and potentially oncometabolites. Successful management of liver neoplasms 
requires early diagnosis and careful surveillance for liver neoplasms in the regular follow-up 




Fig. 1. Liver imaging of case 2. (A) A rounded, heterogeneous, predominantly hyperechoic 
approximately 2 x 2 cm lesion (B) with minimal internal vascularity was detected on 
ultrasound examination. (C) The lesion projects to segment VII of the liver (*) and is 
relatively inconspicuous on computed tomography, which also depicts the multicystic 
dysplastic right kidney and pelvicalyceal/ureteric dilatation of both kidneys. 
Figure 2 
Fig. 2. Haematoxylin/eosin staining and immunostaining in liver histology of case 2. (A) 
Explanted liver tissue displaying mixed hepatoblastoma comprising embryonal and foetal 




type epithelium; arrow indicates the embryonal component; inset shows nuclear beta catenin 
expression in the embryonal component (plus sign) and absent nuclear beta catenin expression 
in the adjacent foetal component (star). Bile salt export pump expression was not 
demonstrated in the hepatoblastoma component (not shown). (B) Mesenchymal elements 
were present in the form of osteoid. (C) A well differentiated hepatocellular carcinoma 
component demonstrating steatosis with unpaired arteriole-like vessels and stromal invasion; 
arrow in steatotic component indicates unpaired vessel expressing canalicular bile salt export 
pump (inset, small arrow). (D) The background liver demonstrated porto-portal fibrosis with 
mild steatosis, well glycogenated hepatocytes and mild porto-lobular activity. 
Figure 3 
Fig. 3. Histology of liver biopsy and resected liver of case 3. (A) Biopsy from left to right 
displaying extensive necrosis and a tiny focus of vital cells, surrounded by inflammation. 
High power view revealing disturbed liver architecture and highly atypical cells with 
hepatocytic differentiation, silver stain (S) demonstrating focal loss of reticulin fibres, and 
immunostaining shows a strong reactivity for glutamine synthetase (GS) and (B, BC) nuclear 
beta catenin. (C) Liver resection showing entirely necrotic tumour nodules (overview), 
surrounded by a rim of fibrosis and inflammation (inset, plus sign) and shadowy necrotic 
tumour cells, reminiscent of hepatocellular carcinoma (inset, star). (D, Sirius red stain on 
right) Liver resection displaying subtle changes in the non-tumorous tissue including some 
portal tracts lacking clearly identifiable portal vein branches (stars), occasional foci of mostly 
portal inflammation (arrow heads), and occasional hepatocytes with glycogenated nuclei 




(arrows). Stainings are haematoxylin/eosin except where specifically mentioned; 
immunostainings performed as previously described (Friemel et al 2015). 
Figure 4 
Fig. 4. MMUT deficiency induces various metabolic disturbances promoting oncogenesis 
in MMA. Orange arrows with circled minus indicate inhibitory effects; blue arrows indicate 
metabolic pathways; dashed arrows blue arrows indicate the reaction of accumulating 
propionyl-CoA with oxaloacetate to form 2-methylcitrate (2-MCA) and the accumulation of 
methylmalonic acid (MMAcid); black arrows indicate causal relationships supported by 
literature; the black dashed arrow suggests a potential origin of oncometabolites in MMA. 
MUT, methylmalonyl-CoA mutase; PDHc, pyruvate dehydrogenase complex; TCA cycle, 
tricarboxylic acid cycle; mtDNA, mitochondrial DNA; key metabolites in grey; small 
upwards arrows indicate increase of compounds. 
Supplementary Figure 1 
Supp. Fig. 1. Ultrasound and magnetic resonance imaging of kidneys of case 2. (A) Large 
right multicystic dysplastic kidney with (B) severe pelvicalyceal and ureteric dilatation, (C) as 
confirmed on magnetic resonance T2-weighted imaging with contrast. (D) The left kidney is 
normal in size however bright in echogenicity with moderate pelvicalyceal and ureteric 
dilatation. 
Supplementary Figure 2 
Supp. Fig. 2. Long-term biochemical monitoring of case 2. (A) Ammonia (NH3) levels 
(reference <40 µmol/L) improved after liver transplant (LT, dashed vertical line) at the age of 




6 months. (B) Elevations of alkaline phosphatase (ALP, reference range 70-347 U/L) and 
gamma-glutamyl transferase (GGT, reference range 20-132 U/L) normalised after LT. (C) 
Significantly raised alpha-fetoprotein (AFP, reference <10 ng/mL) as one of the diagnostic 
markers of hepatoblastoma was no longer in the pathological range after tumour resection. 
(D) Alanine transaminase (ALT, reference range 9-40 U/L) and aspartate transaminase (AST, 
reference range 21-80 U/L) levels were interpreted to have peaked post-transplant due to a 
viral cause, affecting the newly implanted liver. 
 





 Case 1 Case 2 Case 3 Case 4 Case 5 
Demographics          
Gender Female Male Female Male Male 
Ethnicity Caucasian Pakistani Caucasian Caucasian N/A 
          
MMA          
Age of diagnosis 10 days 5 days
&
 5 days 10 days on NBS 
Onset
β
 Early Early Early Early Early 
Clinical hydroxocobalamin 
responsiveness 



















MMUT activity (fibroblast 
studies) 
N/A N/A 1% of control Undetectable N/A 
Plasma/urinary MMA level 
ω
 plasma MMA 
(median): 1760 
µmol/L (range 
310 to 3300) 
plasma MMA 
(median): 134 





221 to 3420) 
urinary MMA: 








          
Liver disease/neoplasm          
Age at diagnosis of liver 
neoplasm 
22 yrs 5 mos 4 mos 1 wk 30 yrs 11 yrs 1 yr 7 mos 
Elevated liver enzymes ALP, ALT ALP, GGT ALP, AST, GGT ALT, AST N/A 
Alpha-fetoprotein levels 
(normal <10) [ng/mL] 
N/A 23,780 9 73 500,000 
Subtype of liver neoplasm HCC HB, HCC HCC HB (resembling 
adult HCC) 
HB 





age 6 months 
with subsequent 
chemotherapy 















          
Renal disease          
Stage of renal disease CKD 4 CKD 2 CKD 4 CKD 4 N/A 
corrGFR [ml/min/1.73m^2] 22 87 24 20 N/A 
Kidney transplant No No No Yes (at 9 yrs 8 
mos of age) 
Yes (at 2 yrs 3 
mos of age as 
domino liver-






          
Outcome          
Survival Deceased (at 22 
yrs 5 mos) 
Alive Deceased (at 32 
yrs)  
Deceased (at 11 
yrs) 
Alive 









to liver neoplasm 
N/A 
Table 1. Overview of five MMA cases who presented with a liver neoplasm. Information was extracted from literature for published cases 4 
(Cosson et al 2008) and 5 (Chan et al 2015). NBS, newborn screening; ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate 
transaminase; GGT, gamma-glutamyltransferase; HB, hepatoblastoma; HCC, hepatocellular carcinoma; N/A, not available; CKD, chronic kidney 
disease; corrGFR, glomerular filtration rate, corrected for body surface. 
&
 Diagnosis made upon sibling screen. 
β
 Early corresponds to neonatal onset, i.e. ≤28 days of age. 





 Plasma MMA levels were assessed in metabolically well-controlled state and are based on 15 (case 1), ten (case 2, pre-transplant), and 14 (case 3) 
individual measurements, collected over a period of 2 years (case 1), 6 months (case 2), and 4 years (case 3), respectively. 
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